Gain Therapeutics presents positive Phase 1b rexaceract extension data
Gain Therapeutics said Phase 1b open-label extension data for rexaceract showed further evidence of disease-modifying activity through 12 months of administration.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.